<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901225</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00014563</org_study_id>
    <nct_id>NCT00901225</nct_id>
  </id_info>
  <brief_title>Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant</brief_title>
  <official_title>Plerixafor Rescue Mobilization For Autologous Stem Cell Transplant Patients With Inadequate Response to G-CSF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte
      colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both
      healthy volunteers and cancer patients. Furthermore, in cancer patients, cells collected via
      apheresis using Plerixafor and G-CSF have been successfully transplanted. In December 2008,
      Plerixafor received approval from the Food and Drug administration for use in combination
      with G-CSF to aid in mobilization of progenitor cells for apheresis. The proposed study is
      not designed to support approval of a new indication or change in the advertising for
      Plerixafor. The route of administration and dosage level are identical to that which is
      listed on the package insert. Although Plerixafor is not approved for patients with Hodgkins
      Lymphoma, there is no known or theoretic increased risk of the use of this drug in this
      patient population.

      The study hypothesis for this study is that patients with a circulating CD34+ count &lt; 20
      cells/ul after 5 days of mobilization with G-CSF alone will achieve &gt; or equal to 2 X
      10(6)CD34+ cells/kg within 3 days of apheresis after receiving Plerixafor with G-CSF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, Phase 2, open-label study. All patients diagnosed with non-hodgkins
      lymphoma, hodgkins disease or multiple myeloma and candidates for autologous transplantation
      are eligible to enter into the study. The only change to the standard of care is the addition
      of 240 ug/kg Plerixafor following 5 days of (G-CSF) mobilization.

      The results of the study will provide both numeric and categorical estimates of measurements
      of the safety and efficacy of Plerixafor. The primary efficacy endpoint, Treatment Success,
      is a binary response variable categorizing whether the patient was able to mobilize at least
      2 X 10(6) CD34+ cells/kg within 3 days of apheresis.

      The percentage of patients achieving Treatment Success will be summarized. All AEs will be
      followed for 30 days after the last apheresis or until the first dose of ablative
      chemotherapy, whichever occurs first. All SAEs will be followed for 6 months post-transplant
      or until relapse. All patients who receive at least one dose of Plerixafor will be included
      in all summaries of AEs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Achieved &gt; or Equal to 2 X 10(6)CD34+ Cells/kg Within 3 Days of Apheresis After Receiving Plerixafor With G-CSF.</measure>
    <time_frame>5 days after receiving G-CSF</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing a Grade III/IV Toxicity</measure>
    <time_frame>6 months post transplant or until relapse</time_frame>
    <description>Safety of plerixafor as measured by Grade III/IV Toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Graft Failure</measure>
    <time_frame>12 months</time_frame>
    <description>To investigate the hematological activity of Plerixafor as measured by Graft Failure. Graft failure is defined as failure of initial engraftment (primary graft failure) or initial engraftment, but subsequent loss of hematopoiesis (secondary graft failure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to Absolute Neutrophil Count &gt;500</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Durability of Engraftment</measure>
    <time_frame>12 months</time_frame>
    <description>Durability of engraftment is defined as the duration and stability of hematopoiesis following autologous transplantation. Subjects who experience durable engraftment have neutrophil counts greater than 500 and platelet counts greater than 20,000 within the specified time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Engraftment</measure>
    <time_frame>12 months</time_frame>
    <description>Days to platelet count &gt;20,000</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkins Lymphoma</condition>
  <condition>Hodgkins Disease</condition>
  <arm_group>
    <arm_group_label>G-CSF plus Plerixafor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF plus Plerixafor</intervention_name>
    <description>On Day 5 of G-CSF mobilization,
if the patient's peripheral CD34+ cell count is &lt; 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.
if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is &lt; 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected.</description>
    <arm_group_label>G-CSF plus Plerixafor</arm_group_label>
    <other_name>Mozobil, AMD3100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 75 years.

          -  Diagnosis of NHL, HD or MM

          -  Eligible for autologous transplantation

          -  CD34+ cell count &lt; 7 cells/ul after 5 days of mobilization with G-CSF or CD34+ cell
             count between 7 and 19 (inclusive) on day 5 of mobilization with G-CSF and &lt; 1.3 x 106
             CD34+ cells collected by apheresis on day 5 of G-CSF therapy.

          -  &lt; or equal to 5 prior regimens of chemotherapy (Rituxan is not considered chemotherapy
             for the purpose of this study)

          -  ≥ 3 weeks since last cycle of chemotherapy and the beginning of G-CSF mobilization
             (Rituxan and Lenalidomide are not considered chemotherapy for the purpose of this
             study)

          -  Total dose of melphalan &lt; or equal to 200 mg

          -  ECOG performance status of 0 or 1

          -  Recovered from all acute toxic effects of prior chemotherapy

          -  Absolute PMN count &gt; 1.0 X 10(9)/l prior to first dose of G-CSF

          -  PLT count &gt; 75 X 10(9)/l prior to first dose of G-CSF

          -  Serum creatinine &lt; or equal to 2.5 mg/dl

          -  SGOT, SGPT and total bilirubin &lt; 2 X upper limit of normal (ULN) prior to the first
             dose of G-CSF

          -  Cardiac and pulmonary status sufficient to undergo apheresis and transplantation as
             determined by standard institutional practice

          -  Signed informed consent

          -  Patients of childbearing potential agree to use an approved form of contraception

        Exclusion Criteria:

          -  A co-morbid condition which, in the view of the investigator, renders the patient at
             high risk from treatment complications

          -  Failed previous stem cell collection or collection attempts

          -  A residual acute medical condition resulting from prior chemotherapy

          -  Active brain metastases or carcinomatous meningitis

          -  Active infection requiring antibiotic treatment (excluding controlled catheter-related
             bacteremia)

          -  Received prior radio-immunotherapy with Zevalin or Bexxar

          -  Received thalidomide, dexamethasone, and/or Velcade within 7 days prior to the first
             dose of G-CSF

          -  Positive pregnancy test in female patients

          -  Lactating females

          -  Patients who previously received experimental therapy within 4 weeks of enrolling in
             this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Horwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <results_first_submitted>October 30, 2013</results_first_submitted>
  <results_first_submitted_qc>April 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2014</results_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was enrolled in April 2005 and the final patient enrolled in August 2010. The protocol was closed to accrual for approximately 3.5yrs, so the total time to protocol activation was 15 months. This was a single institution study (Duke adult stem cell transplant program).</recruitment_details>
      <pre_assignment_details>All patients deemed to be poor mobilizers to G-CSF as a single agent, were eligible for enrollment (assuming protocol eligibility criteria were met).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-CSF Plus Plerixafor</title>
          <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>G-CSF Plus Plerixafor</title>
          <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieved &gt; or Equal to 2 X 10(6)CD34+ Cells/kg Within 3 Days of Apheresis After Receiving Plerixafor With G-CSF.</title>
        <time_frame>5 days after receiving G-CSF</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Plus Plerixafor</title>
            <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved &gt; or Equal to 2 X 10(6)CD34+ Cells/kg Within 3 Days of Apheresis After Receiving Plerixafor With G-CSF.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing a Grade III/IV Toxicity</title>
        <description>Safety of plerixafor as measured by Grade III/IV Toxicity</description>
        <time_frame>6 months post transplant or until relapse</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Plus Plerixafor</title>
            <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing a Grade III/IV Toxicity</title>
          <description>Safety of plerixafor as measured by Grade III/IV Toxicity</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Graft Failure</title>
        <description>To investigate the hematological activity of Plerixafor as measured by Graft Failure. Graft failure is defined as failure of initial engraftment (primary graft failure) or initial engraftment, but subsequent loss of hematopoiesis (secondary graft failure).</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Plus Plerixafor</title>
            <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Graft Failure</title>
          <description>To investigate the hematological activity of Plerixafor as measured by Graft Failure. Graft failure is defined as failure of initial engraftment (primary graft failure) or initial engraftment, but subsequent loss of hematopoiesis (secondary graft failure).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Absolute Neutrophil Count &gt;500</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Plus Plerixafor</title>
            <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Absolute Neutrophil Count &gt;500</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="10" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Durability of Engraftment</title>
        <description>Durability of engraftment is defined as the duration and stability of hematopoiesis following autologous transplantation. Subjects who experience durable engraftment have neutrophil counts greater than 500 and platelet counts greater than 20,000 within the specified time frame.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Plus Plerixafor</title>
            <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Durability of Engraftment</title>
          <description>Durability of engraftment is defined as the duration and stability of hematopoiesis following autologous transplantation. Subjects who experience durable engraftment have neutrophil counts greater than 500 and platelet counts greater than 20,000 within the specified time frame.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Engraftment</title>
        <description>Days to platelet count &gt;20,000</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Plus Plerixafor</title>
            <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Engraftment</title>
          <description>Days to platelet count &gt;20,000</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="10" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>G-CSF Plus Plerixafor</title>
          <description>Patients who were unable to mobilize a minimum number of cells (CD34+ cell count &lt;20 cells/ul)following 5 days of G-CSF mobilization.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>fever of unknown origin without clinically or microbiologically documented infection)(ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mitchell E Horwitz, MD, Principal Investigator</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-668-1045</phone>
      <email>mitchell.horwitz@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

